Australia's most trusted
source of pharma news
Tuesday, 21 January 2025
Posted 10 July 2024 PM
Eli Lilly has signed an agreement to purchase biopharma Morphic for $4.75 billion (US$3.2 billion) in a move that bolsters its position in the inflammatory bowel disease market.
The drawcard is MORF-057, a selective oral small molecule inhibitor of alpha-four-beta-seven integrin which results in gut-selective anti-inflammatory activity, for the treatment of inflammatory bowel disease.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.